Key Developments For EntreMed, Inc.
EntreMed, Inc. (ENMD.O) (Consolidated Issue listed on NASDAQ Capital Market)
EntreMed, Inc. Announces Results Of ENMD-2076 Phase I Study In Advanced Cancer Patients
EntreMed, Inc. announced that presentation of clinical data for its Aurora A/angiogenic kinase inhibitor, ENMD-2076. ENMD-2076, a small molecule, oral kinase inhibitor that targets Aurora A and other kinases critical to angiogenesis, cellular growth and proliferation, was studied in patients with refractory solid tumors. Data from the 25 patients who participated demonstrated that ENMD-2076 administered orally in daily doses is associated with clinical benefit as determined by reductions in tumor volume, reductions in tumor markers, and improvement in cancer-related symptoms. These benefits were demonstrated in patients with a variety of tumor types including melanoma, renal cell, ovarian and colorectal cancer. ENMD-2076 was well-tolerated when administered daily. In addition, plasma soluble KDR (VEGFR2), a marker of effect against the VEGF receptor, was reduced in all patients when compared to baseline. Side effects included hypertension and low blood counts, consistent with the known targets of ENMD-2076. Plasma concentrations at the higher dose levels evaluated were within the range of where there was excellent antitumor activity in preclinical models.
EntreMed, Inc. Comments On FY 2009 Revenue Guidance
EntreMed, Inc. announced that for fiscal 2009, it expects revenues will remain consistent with 2008.
EntreMed, Inc. Says Chief Executive Officer And Chief Financial Officer To Leave; Cuts 60% Jobs-Reuters
Reuters reported that EntreMed, Inc. said that it would cut about 60% jobs and announced a string of management changes to preserve capital and focus on the development of its advanced drug candidate. The Company also said that its Chief Executive Officer James Burns will be leaving the Company along with Chief Financial Officer Dane Saglio to reduce further cost.
EntreMed, Inc. Initiates ENMD-2076 Clinical Trial In Multiple Myeloma
EntreMed, Inc. announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients. The study will be conducted at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. Dr. Sherif Farag, Associate Professor, Department of Medicine, will serve as principal investigator. Primary objectives for the dose escalation study include determining the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ENMD-2076 when administered orally once a day in patients with multiple myeloma who are refractory to other drug therapy. The study will also assess the safety, tolerability, pharmacodynamic effects and activity of ENMD-2076 in this patient population.
EntreMed, Inc. Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
EntreMed, Inc. announced that it has met the primary endpoint for the efficacy portion of the open label Phase 1/2 study of MKC-1 in combination with pemetrexed (Alimta) in non-small cell lung cancer patients.
